Rezolute, Inc. (RZLT)
Automate Your Wheel Strategy on RZLT
With Tiblio's Option Bot, you can configure your own wheel strategy including RZLT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RZLT
- Rev/Share 0.0
- Book/Share 1.7185
- PB 5.72
- Debt/Equity 0.01
- CurrentRatio 14.3674
- ROIC -0.4865
- MktCap 892839751.0
- FreeCF/Share -0.7322
- PFCF -12.9257
- PE -12.4625
- Debt/Assets 0.0092
- DivYield 0
- ROE -0.6503
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RZLT | Guggenheim | -- | Buy | -- | $11 | Aug. 27, 2024 |
News
Rezolute Stock: FDA Fast Track Fuels 2025 Breakout
Published: September 17, 2025 by: MarketBeat
Sentiment: Positive
Rezolute, Inc.'s NASDAQ: RZLT stock price is steadily moving higher in 2025 and is expected to continue its run because of what adds up to a rapidly improving outlook. Its lead pharmaceutical candidate, Ersodetug, was granted the FDA's Breakthrough Therapy designation, which puts it on a fast track for approval.
Read More
Rezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Published: September 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Rezolute, Inc. (NASDAQ:RZLT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 12:20 PM EDT Company Participants Nevan Elam - Founder, CEO, Principal Financial Officer & Acting Chairman of the Board Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy All right. Good afternoon, everyone.
Read More
Rezolute to Participate in Upcoming Investor Conferences
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Read More
Rezolute to Participate in Upcoming Investor Conferences
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Read More
Rezolute: RZ402 Could Be A Surprise Candidate In The Making
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 study using the oral small molecule plasma kallikrein inhibitor RZ402 for the treatment of patients with diabetic macular edema. The global diabetic macular edema market size is projected to reach $7.5 billion by 2034.
Read More
Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock?
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Rezolute (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Rezolute: Late-Stage Study Targeting Hyperinsulinism
Published: February 18, 2025 by: Seeking Alpha
Sentiment: Positive
Rezolute is a microcap biopharma focused on developing therapies for hypoglycemia caused by hyperinsulinism, with promising late-stage trials for RZ358 and RZ402. RZ358 targets Congenital Hyperinsulinism and Tumor Hyperinsulinism, showing significant efficacy in reducing hypoglycemia in phase 2 trials. Financially, RZLT has a market cap of $279mn, $105mn in cash, and a cash runway of 5–7 quarters, with manageable expenses.
Read More
About Rezolute, Inc. (RZLT)
- IPO Date 2013-01-14
- Website https://www.rezolutebio.com
- Industry Biotechnology
- CEO Nevan Charles Elam
- Employees 64